With the recent approval of anti-LAG-3 ICIs for the treatment of metastatic melanoma, a better understanding of the role of the melanoma TME and mechanisms mediating patient response to anti-PD-1 monotherapy compared to combination therapy with anti-CTLA-4 or LAG-3, is clearly needed [9]. This evidence concerns the gene LAG3 and melanoma.